Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03709342 | A PK/PD Study of CM4620-IE in Patients With Acute Pancreatitis | PHASE2 | COMPLETED | 7 | — | — | Jan 6, 2019 | Jun 7, 2019 | May 3, 2022 | 1 | United States |
Outcome assessed the percent change in IL-2 production after the administration of a single dose of CM4620-IE as compared to baseline production, for all patients enrolled. This measurement was to explore if there was a change in IL-2 levels with acute pancreatitis after the administration of a single dose of CM4620-IE.
| Arm | Type | Description |
|---|---|---|
| All Patients | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CM4620-IE | DRUG | single IV infusion on Day 1 over 4 hours |
Inclusion Criteria: 1. Diagnosis of acute pancreatitis established by the presence of abdominal pain consistent with acute pancreatitis, and 1 of the following 2 criteria: 1. Serum lipase and/or serum amylase \> 3 times the upper limit of normal (ULN); 2. Characteristic findings of acute pan...